Search research articles
Contact Us
Filters
Showing results (31-40 of 204) with videos related to
Page
of 21
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 14, 2011
Crizotinib and testing for ALK
Alice T Shaw, Benjamin Solomon, Mari Mino Kenudson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2015
Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine
Ryohei Katayama, Christine M Lovly, Alice T Shaw
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2005
Future of early detection of lung cancer: the role of mouse models
Alice T Shaw, David G Kirsch, Tyler Jacks
Lung Cancer (Auckland, N.Z.)
|
February 18, 2017
Targeted inhibition in tumors with ALK dependency
Eunice L Kwak, Jeffrey W Clark, Alice T Shaw
Nature Cancer
|
February 16, 2023
ALK-positive lung cancer: a moving target
Jaime L Schneider, Jessica J Lin, Alice T Shaw
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2019
BRAF Mutation Class and Clinical Outcomes-Response
Ibiayi Dagogo-Jack, Mark M Awad, Alice T Shaw
Nature Reviews. Clinical Oncology
|
December 24, 2014
Developing biomarker-specific end points in lung cancer clinical trials
Joel W Neal, Justin F Gainor, Alice T Shaw
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2016
Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics
Jennifer S Temel, Alice T Shaw, Joseph A Greer
Cancer Discovery
|
January 27, 2017
Targeting ALK: Precision Medicine Takes on Drug Resistance
Jessica J Lin, Gregory J Riely, Alice T Shaw
The New England Journal of Medicine
|
September 20, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1
Mark M Awad, Jeffrey A Engelman, Alice T Shaw
Page
of 21
Search research articles
Search
Showing results (31-40 of 204) with videos related to
Sort By:
Page
of 21
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 14, 2011
Crizotinib and testing for ALK
Alice T Shaw, Benjamin Solomon, Mari Mino Kenudson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2015
Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine
Ryohei Katayama, Christine M Lovly, Alice T Shaw
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2005
Future of early detection of lung cancer: the role of mouse models
Alice T Shaw, David G Kirsch, Tyler Jacks
Lung Cancer (Auckland, N.Z.)
|
February 18, 2017
Targeted inhibition in tumors with ALK dependency
Eunice L Kwak, Jeffrey W Clark, Alice T Shaw
Nature Cancer
|
February 16, 2023
ALK-positive lung cancer: a moving target
Jaime L Schneider, Jessica J Lin, Alice T Shaw
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2019
BRAF Mutation Class and Clinical Outcomes-Response
Ibiayi Dagogo-Jack, Mark M Awad, Alice T Shaw
Nature Reviews. Clinical Oncology
|
December 24, 2014
Developing biomarker-specific end points in lung cancer clinical trials
Joel W Neal, Justin F Gainor, Alice T Shaw
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2016
Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics
Jennifer S Temel, Alice T Shaw, Joseph A Greer
Cancer Discovery
|
January 27, 2017
Targeting ALK: Precision Medicine Takes on Drug Resistance
Jessica J Lin, Gregory J Riely, Alice T Shaw
The New England Journal of Medicine
|
September 20, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1
Mark M Awad, Jeffrey A Engelman, Alice T Shaw
Page
of 21